Support

Merck Mectizan Donation Program

Onchocerciasis, or river blindness, is a leading cause of infectious blindness in the developing world. The Merck Mectizan Donation Program (MDP) was launched in 1987, when Merck & Co., Inc. announced that it would donate Mectizan (ivermectin), for the treatment of onchocerciasis to all who needed it for as long as needed.

Medical Product Donations Fellowship Program

In countries where pharmaceuticals, medical equipment, and other supplies are difficult to acquire on a regular basis, medical products donations become a major means of obtaining these critical commodities. The Partnerships for Quality Medical Donations (PQMD) estimates that in countries where medical products are in short supply, medical donations account for as much as half of all medical supplies. Johnson & Johnson supports the Medical Product Donations Fellowship Program.

Medical Mission Sisters

With funding assistance from Johnson & Johnson, the Medical Mission Sisters group cares for more than 1,000 people affected by HIV/AIDs in one of the poorest areas of Nairobi, Kenya. The group also runs a hospice facility and IV Rehydration Unit, distributes food to families with sick parents, and provides educational programs for deaf and handicapped youth.

Lilly MDR-TB Partnership

The Lilly MDR-TB Partnership involves transferring Lilly's proprietary manufacturing technology to partner companies.

Leprosy Elimination

Novartis is providing free treatment for leprosy patients worldwide through its multi-drug therapy.

LEEM Quality Control Program

Counterfeit and substandard medicines are a major threat to health in developing countries, many of which lack the technical resources to identify inferior quality medicines. To help alleviate this situation, the association representing the R&D pharmaceutical industry in France, Les Entreprises du Medicament (LEEM), started a program in 2006 to allow developing countries to send samples of suspect medicines to France for analysis. To ensure impartiality, the LEEM pays for samples to be analyzed by an independent expert body, the Central Humanitaire Medico Pharmaceutique (CHMP).

JPMA: Strengthening Quality Control in Asia

The Japan Pharmaceutical Manufacturers Association (JPMA) helps developing countries in Asia to establish efficient pharmaceutical distribution and quality control systems, via the following activities: Training in Japan: Since 1989, the JPMA has worked with the World Health Organization to provide annual Quality Control training courses in Japan for Asian government quality control personnel. JPMA provides practical training in medicines quality control at research laboratories and manufacturing plants, with the help of its member companies.

JPMA: Anti-Counterfeiting Program in Cambodia

The Japan Pharmaceutical Manufacturers Association (JPMA), Kanazawa University and the Cambodian Ministry of Health started a joint project to combat counterfeit medicines in Cambodia in 2006. Surveys conducted from 2006 to 2010 have detected counterfeit drugs sold without packaging and substandard drugs, mainly from local manufacturers and sold via illegal pharmacies.

Johnson & Johnson Burn Treatment Center (JJBTC) in Soweto

In 1990, the company built the Johnson & Johnson Burn Treatment Centre at the Chris Hani Baragwanath Hospital in Soweto, South Africa. The JJBTC has 24 beds for adults and 26 beds for children, an operating room, and multi-disciplinary facilities and treats about 1,500 people a year. This state-of-the-art unit treats more than 1,500 patients annually for serious and complicated burns, and has succeeded in reducing the mortality rate among critically ill patients.

International Trachoma Initiative (ITI)

The International Trachoma Initiative (ITI) is the only organization dedicated solely to the elimination of blinding trachoma.

Pages